Hospital.Help

New Haven/Connecticut – Treatment with the “twincretin” tirzepatide, which stimulates both GLP-1 and GIP receptors, reduced body weight by more than 20% and reduced the risk of diabetes in obese and prediabetic patients in a phase 3 study reduced by more than 90%. The preventive effect gradually diminished after the end of treatment. The results of the study were recently presented at ObesityWeek 2024 and now…